Abiraterone Acetate Versions for Treatment of mCRPC

Author(s):

Jose De La Cerda III, MD, MPH

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Bone Predominant mCRPC Patient Case

EP: 2.Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Now Viewing

EP: 3.Abiraterone Acetate Versions for Treatment of mCRPC

EP: 4.Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP: 5.Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP: 6.Patient with mCRPC and Hepatic Disease

EP: 7.Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Video content above is prompted by the following:

Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?

Related Videos

Addressing Remaining Unmet Needs in mCRPC

Use and Sequencing of Novel Treatments in NMIBC

The DORA Trial

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Clinical Perspectives on Early Use of RAD-ENZ

Treatment Selection for mCRPC

Other Investigational Drug Delivery Systems in NMIBC

Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

The Future of RAD-ENZ Combination Therapy